These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 33224141)

  • 21. No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer.
    Otto W; Denzinger S; Bertz S; Gaumann A; Wild PJ; Hartmann A; Stoehr R
    Int J Cancer; 2009 Nov; 125(9):2205-8. PubMed ID: 19621447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.
    Knowles MA
    World J Urol; 2007 Dec; 25(6):581-93. PubMed ID: 17912529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Urothelial carcinoma of the bladder in patients aged 30 years or younger: clinicopathological analysis and expression of fibroblast growth factor receptor 3 (FGFR3) of 45 cases.
    Huang H; Sun M; Li X; Jin J
    Med Oncol; 2015 May; 32(5):137. PubMed ID: 25801230
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience.
    Rose TL; Weir WH; Mayhew GM; Shibata Y; Eulitt P; Uronis JM; Zhou M; Nielsen M; Smith AB; Woods M; Hayward MC; Salazar AH; Milowsky MI; Wobker SE; McGinty K; Millburn MV; Eisner JR; Kim WY
    Br J Cancer; 2021 Oct; 125(9):1251-1260. PubMed ID: 34294892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
    Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
    BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MMP-1 and Pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer.
    Du X; Lin BC; Wang QR; Li H; Ingalla E; Tien J; Rooney I; Ashkenazi A; Penuel E; Qing J
    Clin Cancer Res; 2014 Dec; 20(24):6324-35. PubMed ID: 25326231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance.
    Jing W; Wang G; Cui Z; Xiong G; Jiang X; Li Y; Li W; Han B; Chen S; Shi B
    Cancer Res; 2022 Jan; 82(1):114-129. PubMed ID: 34753771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A place for precision medicine in bladder cancer: targeting the FGFRs.
    di Martino E; Tomlinson DC; Williams SV; Knowles MA
    Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein networking in bladder cancer: immunoreactivity for FGFR3, EGFR, ERBB2, KAI1, PTEN, and RAS in normal and malignant urothelium.
    Røtterud R; Fosså SD; Nesland JM
    Histol Histopathol; 2007 Apr; 22(4):349-63. PubMed ID: 17290345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urothelial Bladder Cancer: Genomic Alterations in Fibroblast Growth Factor Receptor.
    Bou Zerdan M; Bratslavsky G; Jacob J; Ross J; Huang R; Basnet A
    Mol Diagn Ther; 2023 Jul; 27(4):475-485. PubMed ID: 37195586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Loss of heterozygosity at 9q32-33 (DBC1 locus) in primary non-invasive papillary urothelial neoplasm of low malignant potential and low-grade urothelial carcinoma of the bladder and their associated normal urothelium.
    Lopez-Beltran A; Alvarez-Kindelan J; Luque RJ; Blanca A; Quintero A; Montironi R; Cheng L; Gonzalez-Campora R; Requena MJ
    J Pathol; 2008 Jul; 215(3):263-72. PubMed ID: 18452128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy.
    Sung JY; Sun JM; Chang Jeong B; Il Seo S; Soo Jeon S; Moo Lee H; Yong Choi H; Young Kang S; Choi YL; Young Kwon G
    Urol Oncol; 2014 Jan; 32(1):49.e23-31. PubMed ID: 24360661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fibroblast growth factor receptor 3 mutations in epidermal nevi and associated low grade bladder tumors.
    Hernández S; Toll A; Baselga E; Ribé A; Azua-Romeo J; Pujol RM; Real FX
    J Invest Dermatol; 2007 Jul; 127(7):1664-6. PubMed ID: 17255960
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest.
    Miyake M; Ishii M; Koyama N; Kawashima K; Kodama T; Anai S; Fujimoto K; Hirao Y; Sugano K
    J Pharmacol Exp Ther; 2010 Mar; 332(3):795-802. PubMed ID: 19955487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. FGFR inhibition augments anti-PD-1 efficacy in murine FGFR3-mutant bladder cancer by abrogating immunosuppression.
    Okato A; Utsumi T; Ranieri M; Zheng X; Zhou M; Pereira LD; Chen T; Kita Y; Wu D; Hyun H; Lee H; Gdowski AS; Raupp JD; Clark-Garvey S; Manocha U; Chafitz A; Sherman F; Stephens J; Rose TL; Milowsky MI; Wobker SE; Serody JS; Damrauer JS; Wong KK; Kim WY
    J Clin Invest; 2024 Jan; 134(2):. PubMed ID: 38226620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of FGFR3 in bladder cancer: Treatment landscape and future challenges.
    Ascione CM; Napolitano F; Esposito D; Servetto A; Belli S; Santaniello A; Scagliarini S; Crocetto F; Bianco R; Formisano L
    Cancer Treat Rev; 2023 Apr; 115():102530. PubMed ID: 36898352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SIU-ICUD consultation on bladder cancer: basic science.
    McConkey DJ; Lerner SP
    World J Urol; 2019 Jan; 37(1):15-29. PubMed ID: 30547196
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel therapeutic targets in bladder cancer: mutation and expression of FGF receptors.
    Knowles MA
    Future Oncol; 2008 Feb; 4(1):71-83. PubMed ID: 18241002
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer.
    Necchi A; Giardiello D; Mariani L
    Eur Urol; 2017 May; 71(5):840-841. PubMed ID: 27720533
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.